Most analysts on Thursday can agree on one thing: Bristol-Myers Squibb Co.’s agreement to acquire Celgene Corp. is a win for Celgene’s shareholders.

from MarketWatch.com - Top Stories https://on.mktw.net/2Qh9TaN
via IFTTT
from MarketWatch.com - Top Stories https://on.mktw.net/2Qh9TaN
via IFTTT
Kommentare
Kommentar veröffentlichen